Technology | January 05, 2015

FDA Clears Sorin Group Memo 3D ReChord Annuloplasty Ring

Mitral valve annuloplasty ring with chordal guiding system standardizes artificial chord replacement

Sorin Group, Memo 3-D ReChord, annuloplasty ring, mitral valve repair

Image courtesy of Sorin Group

January 5, 2015 — Sorin Group announced U.S. Food and Drug Administration (FDA) clearance for Memo 3-D ReChord, a semi-rigid annuloplasty ring for mitral valve repair.

The device incorporates a chordal guide system into the existing Memo 3-D ring to simplify and standardize the approach to artificial chord replacement. Memo 3-D ReChord’s unique design streamlines mitral repair procedures while allowing surgeons to obtain reproducible results even in advanced chordal reconstructions.

Features include:

  • A unique temporary chordal guide system that simplifies artificial chord replacement
  • Sorin's Carbofilm coating to enhance hemo-compatibility
  • Cell-structure design to accommodate the mitral saddle shape while enabling the physiological 3-D motion of the native annulus.


Steven F. Bolling, M.D., professor of cardiac surgery, University of Michigan Health System, who conducted the first implantation of the ring in the United States, commented on his experience: “The Memo 3D ReChord is simple to use with a minimal learning curve for new users. The chordal guide system gives surgeons more confidence when performing anterior mitral leaflet repairs with Gore-Tex chordae.

I believe that using the Memo 3D ReChord allows surgeons to deliver more reproducible results during this procedure, ultimately improving patient outcomes. Offering a solution that standardizes artificial chord replacement may actually increase the number of anterior mitral leaflet repairs performed each year.”

For more information:

Related Content

Second Micro Interventional Devices Annuloplasty System Successfully Implanted
News | Annuloplasty Rings | October 30, 2017
Micro Interventional Devices Inc. (MID) recently announced the second successful implantation of its MIA (Minimally...
HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings | July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR
News | Annuloplasty Rings | July 20, 2016
New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment...
Mitralign Percutaneous Annuloplasty System, MPAS, CE Mark approval
News | Annuloplasty Rings | April 27, 2016
Mitralign Inc. announced its Mitralign Percutaneous Annuloplasty System (MPAS) has received CE mark approval from its...
Carillon mitral contour system, Cardiac Dimensions, functional mitral regurgitation, FMR, University Hospital Liepzig study
News | Annuloplasty Rings | February 24, 2016
A single-center study noted that treatment with Cardiac Dimensions’ Carillon Mitral Contour System resulted in...
Carillon mitral contour system, cost-effective, optimal medical treatment, OMT, TITAN, functional mitral regurgitation, FMR

Carillon mitral contour system image courtesy of Cardiac Dimensions Inc.

News | Annuloplasty Rings | September 10, 2015
The Carillon mitral contour system is projected to be a cost-effective treatment option when compared to a typical...
Overlay Init